ArticleClinical pharmacology : advances and applications2014
Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study.
Article in Clinical pharmacology : advances and applications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bioactive Compounds from Kefir and Their Potential Benefits on Health: A Systematic Review and Meta-Analysis.Oxidative medicine and cellular longevity · 2021Pooled it
- Treatment of overactive KScientific reports · 2025Trial
- Article
- Common molecular links and therapeutic insights between type 2 diabetes and kidney cancer.PloS one · 2025Article
- Formulation of Glibenclamide proniosomes for oral administration: Pharmaceutical and pharmacodynamics evaluation.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Glycaemic control among type 2 diabetes patients in sub-Saharan Africa from 2012 to 2022: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2022Article
- Ameliorative effects ofSaudi journal of biological sciences · 2022Article
- Evaluation of Antidiabetic and Antihyperlipidemic Activity of 80% Methanolic Extract of the Root ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Small molecule-mediated induction of endoplasmic reticulum stress in cancer cells.RSC medicinal chemistry · 2021Article
- Cathinone: An alkaloid ofSaudi journal of biological sciences · 2021Article
- Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications.Current diabetes reviews · 2020Review
- Effects ofBioImpacts : BI · 2020Article
- Evaluation of the Effect of Glibenclamide in Patients With Diffuse Axonal Injury Due to Moderate to Severe Head Trauma.Trauma monthly · 2016Article
- Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects.Clinical pharmacology : advances and applications · 2016Article
- Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects.Clinical pharmacology : advances and applications · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to investigate the effect of glibenclamide dose escalation on blood glucose and insulin in patients with poorly controlled type 2 diabetes.
methodsTwenty-two subjects with type 2 diabetes were administered increasing doses (0, 2.5, 5, 10, and 20 mg/day) of glibenclamide at 2-week intervals. Glibenclamide, glucose, and insulin determinations were performed.
resultsThe decrease in mean blood glucose from zero dose was 20%, 22%, 26%, and 28% for doses of 2.5, 5, 10, and 20 mg/day, respectively, which was significant from zero dose to 2.5 mg/day (P≤0.001). There were no significant decreases in glucose concentration beyond 2.5 mg/day. The percentage increase in mean insulin from zero dose was 51%, 58%, 44%, and 33% for 2.5, 5, 10, and 20 mg/day respectively. Mean blood insulin increased significantly from zero dose to 2.5 mg/day (P≤0.001). There were no significant increases in mean insulin concentration beyond 2.5 mg/day.
conclusionThe results of this study suggest that increasing doses of glibenclamide do not produce a proportional increase in insulin secretion or a proportional decrease in blood glucose concentration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.